Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion

• Ranjan K. Mohapatra,
• Ahmed Mahal,
• Ahmed Mahal,
• LV Simhachalam Kutikuppala,
• Madhumita Pal,
• Venkataramana Kandi,
• Ashish K. Sarangi,
• Ahmad J. Obaidullah,
• Snehasish Mishra

Affiliations

Ranjan K. Mohapatra

Department of Chemistry, Government College of Engineering, Keonjhar, Odisha, India

Ahmed Mahal

Department of Medical Biochemical Analysis, College of Health Technology, Cihan University—Erbil, Erbil, Kurdistan Region, Iraq

Ahmed Mahal

Guangzhou HC Pharmaceutical Co., Ltd., Guangzhou, China

LV Simhachalam Kutikuppala

Department of General Surgery, Dr NTR University of Health Sciences, Vijayawada, Andhra Pradesh, India

Madhumita Pal

Department of Electrical Engineering, Government College of Engineering, Keonjhar, Odisha, India

Venkataramana Kandi

Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India

Ashish K. Sarangi

Department of Chemistry, School of Applied Sciences, Centurion University of Technology and Management, Odisha, India

Ahmad J. Obaidullah

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Snehasish Mishra

School of Biotechnology, KIIT Deemed-to-be-University, Bhubaneswar, Odisha, India